Table 2. Characteristics of people living with HIV included in this study: shown for 31 December 2023.
| Number of people included | 494 370 |
|---|---|
| Age (median, IQR) | 39 (32–47) |
| Age category | |
| <10 | 4 964 (1%) |
| 10–19 | 11 561 (2%) |
| 20–29 | 72 418 (15%) |
| 30–39 | 167 702 (34%) |
| 40–49 | 149 946 (30%) |
| 50–59 | 66 552 (13%) |
| ≥60 | 21 227 (4%) |
| Female sex (n, %) | 336 466 (68%) |
| Months since ART start (median, IQR) | 81 (41–121) |
| Year of first ART start (median, IQR) | 2017 (2013–2020) |
| Grouped year of first ART start | |
| <2009 | 34 826 (7%) |
| 2009–2013 | 120 139 (25%) |
| 2014–2018 | 149 566 (31%) |
| 2019–2023 | 171 730 (36%) |
| Months since last ART start (median, IQR) | 36 (15–82) |
| ART start CD4 category | |
| >500 | 72 472 (15%) |
| 351–500 | 67 891(14%) |
| 201–350 | 106 176 (22%) |
| <200 | 116 327 (24%) |
| Not available | 130 815 (26%) |
| Last VL category (copies/ml) | |
| >1 000 | 11 761 (4%) |
| 50–999 | 19 139 (6%) |
| <50 | 252 743 (83%) |
| Not available | 22 056 (7%) |
| Last ART regimen | |
| TDF + 3TC/FTC + DTG | 374 617 (77%) |
| TDF + 3TC/FTC + EFV | 59 866 (13%) |
| ABC + 3TC/FTC + DTG | 14 375 (3%) |
| ZDV + 3TC/FTC + DTG | 8 818 (2%) |
| ZDV + 3TC/FTC + LPV/r | 6 233 (1%) |
| Other | 11 757 (2%) |
ART, antiretroviral therapy; VL, viral load.
Cross-sectional distribution across the cyclical cascade
The starting point on both linear and cyclical cascades is the number of people estimated to be living with HIV in the WC. Unfortunately, this estimate is not yet available at a geographical or administrative level below that of the province as a whole.